Dexcom stock shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Ecolab's (ECL) robust performance across the majority of its segments drives its first-quarter sales despite business challenges.